Tiaki Therapeutics has appointed Suzanne Bruhn as CEO. Bruhn, a serial biotech CEO, arrives at Tiaki shortly after the Alzheimer’s disease startup entered into a collaboration with Eisai.

The Dementia Discovery Fund (DDF), an investment vehicle backed by seven big biopharma companies, formed and seeded Tiaki to support efforts to identify modulators of microglial function. Tiaki thinks targeting microglia, immune cells found in the brain, could lead to disease-modifying treatments for a range of neuroinflammatory conditions, starting with Alzheimer’s.